Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
Total Metals Acquires 100% Interest in the High-Grade Pick Lake Critical Minerals Property from Frontier Energy Limited
